Skip to main content
Erschienen in: Clinical Rheumatology 8/2009

01.08.2009 | Original Article

Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up

verfasst von: K. P. Ng, F. Ramos, S. M. Sultan, D. A. Isenberg

Erschienen in: Clinical Rheumatology | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

This study aims to report the concomitant diseases observed and damage outcome in a cohort of patients with adult idiopathic inflammatory myositis (IIM) during long-term follow-up. All patients with IIM were identified from a single centre (follow-up between 1979 and 2006) and fulfilled at least three of the four Bohan and Peter criteria. Patients with inclusion body myositis, juvenile-onset myositis and overt overlap syndromes were excluded. Medical notes were retrospectively reviewed. Concomitant diseases identified were divided into 12 different organ systems (bone, cardiac, respiratory, gastrointestinal, renal, central nervous, malignancy, infection, endocrine, eyes, dermatological and haematological). Patient damage index was calculated using the Myositis Damage Index tool. Fifty-five patients (31 polymyositis, 24 dermatomyositis) were identified. The most prevalent organ system involved was lung with 40 events per 1,000 patient years follow-up. There was significant steroid-related complications with 17/18 patients with bone involvement having osteopenia/osteoporosis. Sjogren's syndrome (n = 3) was the most frequent concomitant auto-immune disease observed. Patients with a higher number of organ systems involved had a significantly higher damage index (r = 0.48, p = 0.001). White patients showed a significant trend to develop more than three other organ system involvement (p < 0.0001) and myositis-related lung disease (p < 0.0001) compared to other races. There is significant steroid-related morbidity in adult IIM patients under long-term follow-up. The prevalence of another concomitant auto-immune disease unlike patients with lupus or Sjogren's syndrome is low.
Literatur
1.
Zurück zum Zitat Ehrenstein MR, Snaith ML, Isenberg DA (1992) Idiopathic myositis: a rheumatological view. Ann Rheum Dis 51(1):41–44PubMedCrossRef Ehrenstein MR, Snaith ML, Isenberg DA (1992) Idiopathic myositis: a rheumatological view. Ann Rheum Dis 51(1):41–44PubMedCrossRef
2.
Zurück zum Zitat Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41(1):22–26CrossRef Sultan SM, Ioannou Y, Moss K, Isenberg DA (2002) Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) 41(1):22–26CrossRef
3.
Zurück zum Zitat Marie I, Hachulla E, Hatron PY et al (2001) Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 28(10):2230–2237PubMed Marie I, Hachulla E, Hatron PY et al (2001) Polymyositis and dermatomyositis: short term and long term outcome, and predictive factors of prognosis. J Rheumatol 28(10):2230–2237PubMed
4.
Zurück zum Zitat Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K (2005) Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 44(1):83–88CrossRef Ponyi A, Borgulya G, Constantin T, Vancsa A, Gergely L, Danko K (2005) Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) 44(1):83–88CrossRef
5.
Zurück zum Zitat Airio A, Kautiainen H, Hakala M (2006) Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 25(2):234–239PubMedCrossRef Airio A, Kautiainen H, Hakala M (2006) Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 25(2):234–239PubMedCrossRef
6.
Zurück zum Zitat Torres C, Belmonte R, Carmona L et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205–215PubMedCrossRef Torres C, Belmonte R, Carmona L et al (2006) Survival, mortality and causes of death in inflammatory myopathies. Autoimmunity 39(3):205–215PubMedCrossRef
7.
Zurück zum Zitat Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM (1996) Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 14(3):263–274PubMed Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM (1996) Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 14(3):263–274PubMed
8.
Zurück zum Zitat Tymms KE, Webb J (1985) Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 12(6):1140–1148PubMed Tymms KE, Webb J (1985) Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 12(6):1140–1148PubMed
9.
Zurück zum Zitat Rios G (2005) Retrospective review of the clinical manifestations and outcomes in Puerto Ricans with idiopathic inflammatory myopathies. J Clin Rheumatol 11(3):153–156PubMedCrossRef Rios G (2005) Retrospective review of the clinical manifestations and outcomes in Puerto Ricans with idiopathic inflammatory myopathies. J Clin Rheumatol 11(3):153–156PubMedCrossRef
10.
Zurück zum Zitat Uthman I, Vázquez-Abad D, Senécal JL (1996) Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 26(1):447–458PubMedCrossRef Uthman I, Vázquez-Abad D, Senécal JL (1996) Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 26(1):447–458PubMedCrossRef
11.
Zurück zum Zitat McDonagh JE, Isenberg DA (2000) Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 59(3):230–232PubMedCrossRef McDonagh JE, Isenberg DA (2000) Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann Rheum Dis 59(3):230–232PubMedCrossRef
12.
Zurück zum Zitat Chambers SA, Charman SC, Rahman A, Isenberg DA (2007) Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Ann Rheum Dis 66(9):1173–1177PubMedCrossRef Chambers SA, Charman SC, Rahman A, Isenberg DA (2007) Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality. Ann Rheum Dis 66(9):1173–1177PubMedCrossRef
13.
Zurück zum Zitat Lazarus MN, Isenberg DA (2005) Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome. Ann Rheum Dis 64(7):1062–1064PubMedCrossRef Lazarus MN, Isenberg DA (2005) Development of additional autoimmune diseases in a population of patients with primary Sjogren's syndrome. Ann Rheum Dis 64(7):1062–1064PubMedCrossRef
14.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347PubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344–347PubMed
15.
Zurück zum Zitat Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407PubMed Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292(8):403–407PubMed
16.
Zurück zum Zitat Vitali C, Bombardieri S, Moutsopoulos HM et al (1993) Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 36(3):340–347PubMedCrossRef Vitali C, Bombardieri S, Moutsopoulos HM et al (1993) Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 36(3):340–347PubMedCrossRef
17.
Zurück zum Zitat Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV (1995) A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 38(9):1218–1224PubMedCrossRef Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV (1995) A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 38(9):1218–1224PubMedCrossRef
18.
Zurück zum Zitat Bronner IM, van der Meulen MF, de Visser M et al (2006) Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 65(11):1456–1461PubMedCrossRef Bronner IM, van der Meulen MF, de Visser M et al (2006) Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis 65(11):1456–1461PubMedCrossRef
19.
Zurück zum Zitat Marie I, Hachulla E, Cherin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622PubMedCrossRef Marie I, Hachulla E, Cherin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47(6):614–622PubMedCrossRef
20.
Zurück zum Zitat Selva-O'Callaghan A, Labrador-Horrillo M, Munoz-Gall X et al (2005) Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 14(7):534–542PubMedCrossRef Selva-O'Callaghan A, Labrador-Horrillo M, Munoz-Gall X et al (2005) Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 14(7):534–542PubMedCrossRef
21.
Zurück zum Zitat Yaqub S, Moder KG, Lacy MQ (2004) Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc 79(5):687–689PubMedCrossRef Yaqub S, Moder KG, Lacy MQ (2004) Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis. Mayo Clin Proc 79(5):687–689PubMedCrossRef
22.
Zurück zum Zitat Grateau G, Roux ME, Franck N et al (1993) Pulmonary hypertension in a case of dermatomyositis. J Rheumatol 20(8):1452–1453PubMed Grateau G, Roux ME, Franck N et al (1993) Pulmonary hypertension in a case of dermatomyositis. J Rheumatol 20(8):1452–1453PubMed
23.
Zurück zum Zitat Kissel JT, Mendell JR, Rammohan KW (1986) Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314(6):329–334PubMed Kissel JT, Mendell JR, Rammohan KW (1986) Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 314(6):329–334PubMed
24.
Zurück zum Zitat Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41(11):729–734PubMedCrossRef Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41(11):729–734PubMedCrossRef
25.
Zurück zum Zitat Hill CL, Zhang Y, Sigurgeirsson B et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100PubMedCrossRef Hill CL, Zhang Y, Sigurgeirsson B et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357(9250):96–100PubMedCrossRef
26.
Zurück zum Zitat Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326(6):363–367PubMedCrossRef Sigurgeirsson B, Lindelof B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326(6):363–367PubMedCrossRef
27.
Zurück zum Zitat Bernatsky S, Boivin JF, Joseph L et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52(5):1481–1490PubMedCrossRef Bernatsky S, Boivin JF, Joseph L et al (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52(5):1481–1490PubMedCrossRef
28.
Zurück zum Zitat Bernatsky S, Clarke AE, Suissa S (2008) Haematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168(4):378–381PubMedCrossRef Bernatsky S, Clarke AE, Suissa S (2008) Haematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168(4):378–381PubMedCrossRef
29.
Zurück zum Zitat Biro E, Szekanecz Z, Czirjak L et al (2006) Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 25(2):240–245PubMedCrossRef Biro E, Szekanecz Z, Czirjak L et al (2006) Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 25(2):240–245PubMedCrossRef
30.
Zurück zum Zitat Koh ET, Seow A, Ong B, Ratnagopal P, Tjia H, Chng HH (1993) Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 52(12):857–861PubMedCrossRef Koh ET, Seow A, Ong B, Ratnagopal P, Tjia H, Chng HH (1993) Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients. Ann Rheum Dis 52(12):857–861PubMedCrossRef
31.
Zurück zum Zitat Shamim EA, Miller FW (2000) Familial autoimmunity and the idiopathic inflammatory myopathies. Curr Rheumatol Rep 2(3):201–211PubMedCrossRef Shamim EA, Miller FW (2000) Familial autoimmunity and the idiopathic inflammatory myopathies. Curr Rheumatol Rep 2(3):201–211PubMedCrossRef
32.
Zurück zum Zitat Marie I, Hachulla E, Cherin P et al (2005) Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 53(2):155–165PubMedCrossRef Marie I, Hachulla E, Cherin P et al (2005) Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 53(2):155–165PubMedCrossRef
33.
Zurück zum Zitat Viguier M, Fouere S, de la Salmoniere P et al (2003) Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 82(2):82–86CrossRef Viguier M, Fouere S, de la Salmoniere P et al (2003) Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 82(2):82–86CrossRef
34.
Zurück zum Zitat Ishida Y, Utikoshi M, Kurosaki M et al (1998) Hepatic veno-occlusive disease in a case of polymyositis associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Intern Med 37(8):694–699PubMedCrossRef Ishida Y, Utikoshi M, Kurosaki M et al (1998) Hepatic veno-occlusive disease in a case of polymyositis associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Intern Med 37(8):694–699PubMedCrossRef
35.
Zurück zum Zitat Miller FW, Rider LG, Chung YL et al (2001) International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40(11):1262–1273CrossRef Miller FW, Rider LG, Chung YL et al (2001) International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40(11):1262–1273CrossRef
36.
Zurück zum Zitat Isenberg DA, Allen E, Farewell V et al (2004) International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43(1):49–54CrossRef Isenberg DA, Allen E, Farewell V et al (2004) International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43(1):49–54CrossRef
37.
Zurück zum Zitat Sultan SM, Allen E, Oddis CV et al (2008) Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 58(11):3593–3599PubMedCrossRef Sultan SM, Allen E, Oddis CV et al (2008) Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 58(11):3593–3599PubMedCrossRef
38.
Zurück zum Zitat Shamim EA, Rider LG, Pandey JP et al (2002) Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 46(7):1885–1893PubMedCrossRef Shamim EA, Rider LG, Pandey JP et al (2002) Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 46(7):1885–1893PubMedCrossRef
39.
Zurück zum Zitat O'Hanlon TP, Rider LG, Mamyrova G et al (2006) HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 54(11):3670–3681PubMedCrossRef O'Hanlon TP, Rider LG, Mamyrova G et al (2006) HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 54(11):3670–3681PubMedCrossRef
Metadaten
Titel
Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up
verfasst von
K. P. Ng
F. Ramos
S. M. Sultan
D. A. Isenberg
Publikationsdatum
01.08.2009
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 8/2009
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1181-4

Weitere Artikel der Ausgabe 8/2009

Clinical Rheumatology 8/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.